Leukemia test kit PNACIamp™

tissuefor RT-PCR

CML (Chronic myelogenous leukemia) patients who has consistently treated with Imatinib (Gleevec), have acquired point mutations in tyrosine kinase domain of BCR-ABL fusion gene. Especially, T315I mutation is known as a mutation associated with Imatinibresistance and observed with high frequency. It is important to monitor patients treated with Imatinibby BCR-ABLfusion gene mutation test to prevent therapy failure due to drug resistance by mutation. FEATURES High sensitivity and specificity even with small amount of DNA(1% LOD with 10 ng wild/mutant type mixed DNA) Real-Time PCR based ready-to-use kit Short running time (within 3 hours)